AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

Patients with actionable genomic alterations were previously treated with an approved targeted therapy and platinum ... as a monotherapy and in combination with other anticancer treatments in various ...

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

AstraZeneca (AZN) and Daiichi Sankyo have submitted a new Biologics License Application ... including an EGFR-directed therapy. The companies have voluntarily withdrawn the BLA in the US for ...

The tenosynovial giant cell tumor (TGCT) trial hit its primary endpoint, teeing up an option decision that could establish ...

The approval of Yescarta means more patients in Scotland can be treated with CAR-T therapy sooner - giving people like ... and get the latest news sent straight to your messages. Daiichi Sankyo’s drug ...

Aileen Lamb, from Edinburgh who had acute myeloid leukaemia said the approval of the new drug gives sufferers hope.

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

TB Alliance is honored to join today's High-Level Meeting hosted by the Indonesian Ministry of Health. Leaders and experts in tuberculosis (TB) have convened to discuss strategies, innovations, and ...

An obvious next step in the development and growth of CAR T-cell therapies has been the jump to solid tumors. Because of ...